XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SEGMENT AND ENTERPRISE-WIDE INFORMATION (Tables)
 3 Months Ended
Jun. 29, 2024
Segment Reporting [Abstract]  
Selected Information by Business Segment
Selected information by reportable segment is presented below:
Three Months Ended
(In thousands)June 29,
2024		July 1,
2023
Net revenues(1)
Plasma$136,042 $139,491 
Blood Center66,839 69,169 
Hospital134,406 102,428 
Net revenues in constant currency337,287 311,088 
Effect of exchange rates(1,115)244 
Net revenues$336,172 $311,332 
(1) Beginning in fiscal 2025, the Company integrated service revenue within its three business units. Prior periods were conformed to current presentation.
Three Months Ended
(In thousands)June 29,
2024		July 1,
2023
Segment operating income
Plasma$65,837 $75,698 
Blood Center22,622 26,283 
Hospital53,891 40,943 
Segment operating income142,350 142,924 
Corporate expenses (1)
(69,980)(75,309)
Effect of exchange rates(1,349)2,613 
Amortization of acquired intangible assets(12,471)(7,473)
Amortization of fair value inventory step-up(5,239)— 
Integration and transaction costs(12,323)(1,115)
Restructuring costs(4,622)11 
Restructuring related costs(2,518)(2,204)
Digital transformation costs(6,345)(3,705)
Impairment of assets and PCS2 related charges— 141 
MDR and IVDR costs(1,126)(1,166)
Litigation-related charges(755)(1,058)
Gain on sale of property, plant and equipment14,134 — 
Operating income$39,756 $53,659 
(1) Reflects shared service expenses including quality and regulatory, customer and field service, research and development, manufacturing and supply chain, as well as other corporate support functions.
Schedule of Revenues by Business Unit and Geographic Regions
Net revenues by business unit are as follows:
  Three Months Ended
(In thousands)June 29,
2024		July 1,
2023
 Plasma$135,910 $139,621 
Apheresis49,094 49,166 
Whole Blood17,151 20,040 
 Blood Center66,245 69,206 
Interventional Technologies(1)
63,044 37,620 
Blood Management Technologies(2)
70,973 64,885 
 Hospital134,017 102,505 
Net revenues(3)
$336,172 $311,332 
(1) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines of the Hospital business unit.
(2) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the Hospital business unit.
(3) Beginning in fiscal 2025, the Company integrated service revenue within its three business units. Prior periods were conformed to current presentation.

Net revenues generated in the Company’s principle operating regions on a reported basis are as follows:
Three Months Ended
(In thousands)June 29,
2024		July 1,
2023
United States$248,902 $237,073 
Japan13,705 11,773 
Europe47,225 39,387 
Rest of Asia19,783 22,040 
Other6,557 1,059 
Net revenues$336,172 $311,332